Supriya Lifescience earnings calls.

Supriya Lifescience delivered an exceptional Q4 FY26 with Rs 277 crore revenueCurrent reported value: Q4 FY26 with Rs 277 crore revenue. No comparable prior figure is available in the source record. (50Current 50 crore vs previous available quarter 11 crore.% YoY), driven by new product launches in cardiovascular intermediates and anesthetics, plus stabilized DSM volumes. Full-year FY26 revenue reached Rs 828 crore (19% YoY)Current reported value: Rs 828 crore (19% YoY). No comparable prior figure is available in the source record., in line with 20% guidance, with EBITDA at Rs 294 crore (35.5Current 35.5 crore vs previous available quarter 34.9 crore.% margin). The USFDA EIR clearance with VAI status from a surprise 7-day inspection across 7 blocks underscores robust compliance culture. Key growth catalysts include the cardiovascular intermediate reaching full 300MT capacity utilizationCurrent reported value: cardiovascular intermediate reaching full 300MT capacity utilization. No comparable prior figure is available in the source record. over FY27-28, Ambernath facility commercializing in semi-regulated markets, and Patal Ganga phase one groundbreaking with Rs 200 crore capex. The company reiterates Rs 1,000 crore FY27 revenue guidanceCurrent reported value: Rs 1,000 crore FY27 revenue guidance. No comparable prior figure is available in the source record. with 20%+ growth trajectory, though quarterly growth will be non-linear due to August maintenance shutdown. Risk includes Ambernath generating minimal revenue in FY27 (full effect in 2-3 years) and EU GMP audit timing slipping to H2 FY27, which delays liquid anesthetic formulation ramp-up.